After ADT and Enz treatment, the number of CXCR2+ cells in PCa increased, and targeting CXCR2 could overcome mCRPC resistance to AR inhibitors such as Enz 24,25. The gene discussed is CXCR2; the disease is posterior cortical atrophy.